Article Text

Download PDFPDF
P53, bcl-2, and bax: Their relationship and effect on prognosis in early stage epithelial ovarian carcinoma
  1. I. Skirnisdóttir1,
  2. B. Sorbe2 and
  3. T. Seidal3
  1. 1Department of Gynecology and Obstetrics, University Hospital, Uppsala;
  2. 2Department of Gynecological Oncology, Örebro Medical Center Hospital, Örebro; and
  3. 3Department of Pathology, Karlstad Medical Center Hospital, Karlstad, Sweden
  1. Address correspondence and reprint requests to: I. Skirnisdóttir MD, Department of Gynecology and Obstetrics, University Hospital, Akademiska sjukhuset, SE-751 85 Uppsala, Sweden.


The prognosis of ovarian carcinoma, even in the early stages (FIGO I–II), continues to present a challenge despite advances in the understanding of pathophysiology and treatment. In a series of 106 patients with epithelial carcinomas in FIGO stages IA–IIC, a number of prognostic factors (age, FIGO stage, histopathologic type, and tumor grade) were studied in relation to important regulators of apoptosis (p53, bcl-2, and bax). Immunohistochemical techniques were used. All the patients received adjuvant radiotherapy after the primary surgery. Univariate analysis showed that expression of p53 was highly significantly associated with tumor grade (P = 0.007) and survival status (P = 0.046). Positive bcl-2 staining was associated with serous (P = 0.0002) and endometrioid tumor subtypes, but not with the survival rate. A positive bax status was associated with younger age (P = 0.012) and a more favorable probability of survival. A significant association between the bcl-2 and bax status of the tumors and histopathologic subtypes and grades was noted. The most favorable subgroup of tumors was that with a combination of positive bax staining and negative p53 staining. In a multivariate Cox analysis, tumor grade (P = 0.0006) and bax status (P = 0.020) were independent and significant prognostic factors.

  • apoptotic regulators
  • bax
  • bcl-2
  • ovarian cancer
  • p53
  • prognostic factors

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.